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Type 2 diabetes mellitus (DM2) is strongly associated with other comorbidities such as obesity, atherosclerosis, and hypertension.
Obesity is associated with sustained low-grade inflammatory response due to the production of proinflammatory cytokines. This
inflammatory process promotes the differentiation of some myeloid cells, including myeloid-derived suppressor cells (MDSCs).
In this study, two groups of individuals were included: DM2 patients and non-DM2 individuals with similar characteristics.
Immunolabeling of CD15+ CD14- and CD33+ HLA-DR-/low was performed from whole peripheral blood, and samples were
analyzed by flow cytometry, and frequencies of MDSCs and the relationship of these with clinical variables, cytokine profile
(measured by cytometric bead array), and anthropometric variables were analyzed. The frequency of CD33+ HLA-DR-/low
MDSCs (that produce IL-10 and TGF-β, according to an intracellular detection) is higher in patients with DM2 (P < 0:05), and
there is a positive correlation between the frequency of CD15+ CD14- and CD33+ HLA-DR-/low MDSC phenotypes. DM2
patients have an increased concentration of serum IL-5 (P < 0:05). Also, a negative correlation between the frequency of CD15+
CD14- MDSCs and LDL cholesterol was found. Our group of DM2 patients have an increased frequency of mononuclear
MDSC CD33+ HLA-DR-/low that produce TGF-β and IL-10. These cytokines have been associated with immune modulation
and reduced T cell responses. DM2 and non-DM2 subjects show a similar cytokine profile, but the DM2 patients have an
increased concentration of IL-5.
1. Introduction
According to the American Diabetes Association (ADA),
diabetes mellitus is a metabolic disease characterized by
severe hyperglycemia due to defects in insulin secretion or
the lack of proper action of this hormone in the target tissues.
Type 2 diabetes mellitus (DM2) is the one that has the great-
est impact worldwide, accounting for 90-95% of all reported
cases of diabetes worldwide as reported by the ADA [1, 2].
The World Health Organization (WHO) estimated that 347
million cases of DM2 exist worldwide as of 2014 [3], and also,
recent estimations suggest that DM2 will be the 7th cause of
mortality by 2030 [4]. Data from the International Diabetes
Federation suggest 4.9 million deaths associated with
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diabetes and its related complications [5]. In Mexico, the
National Institute for Statistics and Geography (INEGI, acro-
nym in Spanish) has reported that 70 out 1000 deaths were
caused by diabetes and its complications causing a great eco-
nomic burden to the national health institutions [6].
It has been described that the main factors associated
with an increased risk of developing DM2 are obesity,
unhealthy eating habits, sedentarism, advanced age, family
history of diabetes, ethnicity, etc. [7–9]. The relationship
between diabetes and obesity has been widely documented,
and around 90% of diabetics are overweight or obese [10].
Obesity has also been associated with low-grade chronic
inflammatory processes, and several cytokines such as tumor
necrosis factor alpha (TNF-α) have been shown to be
elevated in obese individuals due to an increased activity of
adipose tissue-derived cytokine production and insulin
resistance [11, 12]. Other bioactive molecules such as leptin,
IL- (interleukin-) 6, resistin, and monocyte chemoattractant
protein 1 (MCP-1) have been associated with insulin resis-
tance [13–17].
Chronic inflammatory processes have been associated
with alterations in leucocyte composition. In the seventies,
a subset of myeloid cells with suppressor properties was
described in patients with several types of cancer. These cells
were at the moment described as “natural suppressor cells,”
but the functional properties and markers of such cells have
been recently described and named as myeloid-derived
suppressor cells (MDSCs) [18–20]. These cells are a hetero-
geneous group of myeloid cells such as myeloid progenitors,
immature myeloid cells, immature granulocytes, and imma-
ture dendritic cells. In humans, the main MDSCs have been
described as immature monocytic and granulocytic cells,
and several reports suggest an elevation in the frequency of
MDSCs in some pathologic conditions, including cancer,
sepsis, and acute and chronic inflammatory processes [19,
20]. Several phenotypes for these cells have been described
such as CD15+ CD14- and also CD33+ HLA-DR-/low [19]
to mention some [21]. It has been described that these cells
have immune suppressive functions [22], and they are pro-
ducers of interferon gamma (IFN-γ), IL-10, and transform-
ing growth factor beta (TGF-β) [23].
As described previously, obesity is the biggest risk factor
for developing DM2. This has also been associated with
low-grade chronic inflammation with overproduction of
TNF-α, IL-6, and IL-1β and other bioactive molecules in
the adipose tissue such as granulocyte-macrophage colony-
stimulating factor (GM-CSF), granulocyte colony-
stimulating factor (G-CSF), macrophage colony-stimulating
factor (M-CSF), vascular endothelial growth factor (VEGF),
or IFN-γ [24–27]. Taking all the previously described data
and the fact that diabetic individuals with DM2 have a higher
predisposition to infection due to diminished immune
responses [28–30], it becomes really important to understand
if several cell populations that suppress the immune response
such as the MDSCs are major conditioning factors that pro-
mote deficiencies in the development of several immune-
mediated mechanisms in DM2 individuals [19]. The aim of
the present paper was to compare the frequency of myeloid
cells with the phenotypes CD15+ CD14- and CD33+ HLA-
DR-/low producers of IL-10 and TGF-β in peripheral
blood of patients with DM2 and non-DM2 subjects. The
correlation between the MDSC immunophenotypes with
common comorbidities to diabetics, laboratory, cytokine
levels, cell suppressive function, and anthropometric data
was also analyzed.
2. Material and Methods
2.1. Participants’ Inclusion Criteria. DM2 patients of the
study were recruited at the medical family care unit # 4
(Zacatecas, Mexico) according to approved protocols (R-
2011-785-063); the visits were made between March 19
and May 19 in 2015. DM2 subjects (n = 23, age range of
35-62 years old) were invited to participate. DM2 subjects
complied with the ADA criteria for DM2 diagnosis as fol-
lows: random glucose measurement of >120mg/dl and/or
glucose tolerance test > 200mg/dl (for newly diagnosed
individuals) and/or glycated hemoglobin ðHbA1cÞ > 6:5%.
Nondiabetic subjects (non-DM2) (n = 21) were negative
for diabetes according to ADA criteria and were recruited
at the same clinic with that from a similar age group. Clin-
ical and laboratory data from all participants was collected
from the routine follow-up at their clinic. Common
comorbidities (reported by the treating physician) were
also recovered from the medical records.
2.2. Ethics Statement. The present study was approved by the
national commission on scientific investigation (CNIC) at
the Mexican Institute for Social Security (IMSS) as well as
the national ethics commission with registration number R-
2011-785-063. All protocols were based on the International
Declaration of Helsinki and in the principles of not malevo-
lence, justice, and equality. All participants that agreed to
participate signed an informed consent, and blood samples
were drawn from only these individuals.
2.3. MDSC Phenotype and Flow Cytometry Analysis. Immu-
nophenotypes were identified according to Ko et al. [31].
Briefly, blood samples were obtained from the participants
by means of venipuncture. 4ml of blood was collected.
100μl of whole blood was used with a lyse/wash protocol
for staining. For the identification of the MDSC phenotypes,
a combination of the following antibodies was used: CD14
PECy7 and CD15 PE-Cy5 (BD Biosciences, USA); CD33
APC and HLA-DR PerCP-Cy5.5 (BD Biosciences, USA).
All antibodies were titrated before use. Immunostained
samples were analyzed by flow cytometry in a FACSCanto
II (Becton Dickinson, USA) with 488 and 633 laser lines
and a standard configuration of 4-2 detectors. Data acqui-
sition was performed by FACSDiva software v. 6.1 (BD
Biosciences, USA), and 50000 events were acquired for
each sample. The time parameter was used as quality con-
trol, observing stability between the performed analyses.
Analysis of flow cytometry data was carried out in the
FCS 3.0 files after export in FlowJo Software v. 8.7 (FlowJo
LLC, USA).
2.4. Intracellular Staining of IL-10 and TGF-β. Blood samples
were obtained from 4 DM2 patients and 4 nondiabetic
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participants by venipuncture. 100μl of whole blood was used
with a lyse/wash protocol, and for cellular permeabilization,
we used the BD Cytofix/Cytoperm™ Kit (BD Biosciences,
USA) according to the manufacturer’s instructions. Intracel-
lular staining was performed immediately afterwards with
the antibodies for TGF-β PE and IL-10 PE in separate tubes
(BD, Biosciences, USA). Fluorescence minus one (FMO)
was used as the control. Immunostained samples were ana-
lyzed by flow cytometry in a FACSCanto II (Becton Dickin-
son, USA), and analysis of flow cytometry data was carried
out in the FCS 3.0 files after export in FlowJo Software v.
8.7 (FlowJo LLC, USA).
2.5. Cytokine Quantification by Cytometric Bead Array. The
concentration of TNF-α, IFN-γ, IL-1α, IL-5, IL-10, IL-
12p70, IL-17, and eotaxin was analyzed by cytometric bead
array using the manufacturer’s specifications (BD Biosci-
ences, USA). Briefly, starting with cytokine standard prepa-
ration and cytokine capture bead mixture, 50μl serum
samples from each individual and dilutions for the standard
curve were placed in a multiscreen 1.2μm, 96-well filter plate
(Merck Millipore, Germany), and the mixed capture beads
and phycoerythrin detection reagent were added. After 3-
hour incubation and repeated wash steps, the data was
acquired in a FACSCanto II flow cytometer (Becton Dickin-
son, USA) and analyzed using FCAP Array v3.0 (BD Biosci-
ences, USA) to convert fluorescent intensity values to
concentrations using a standard curve.
2.6. Statistical Analysis. Normality of data was verified by
means of a Kolmogorov-Smirnov test or a D’Agostino-
Pearson normality test. Group comparisons for continuous
quantitative variables were made with a Mann-Whitney U
test for the nonparametric data or a Welch corrected t-test
for normally distributed data. Categorical variables were ana-
lyzed with a Fisher exact test. A correlation analysis was
made to explore the correlation of MDSC, laboratory, and
anthropometric data by using a Spearman correlation (non-
normal distribution was verified). The two-tailed level of sig-
nificance used for all analysis was α = 0:05. All statistical
analysis was carried out in the GraphPad Prism software
v6.0 (GraphPad Software, USA).
3. Results
3.1. Clinical Features of Patients with DM2 and Nondiabetic
Controls. Clinical features, laboratory data, and anthropo-
metric data were analyzed in order to determine whether dif-
ferences were present due to heterogeneity of the population
or whether differences in MDSC cells were associated with
other parameters such as metabolic markers of disease or car-
diovascular risk factors. As shown in Table 1, nomajor differ-
ences were identified in the groups in the variables such as
age, sex, body mass index, waist to hip ratio, low-density lipo-
protein cholesterol (cLDL), high-density lipoprotein choles-
terol (cHDL), and total cholesterol. As expected, there were
significant differences between DM2 subjects for both
Hb1Ac% and glucose levels due to the inclusion criteria. No
differences were identified either for markers associated with
alterations in lipid metabolism or cardiovascular risk.
3.2. MDSCs with CD15+ CD14- and CD33+ HLA-DR-/Low
Phenotypes Are Present in Both DM2 and Non-DM2
Subjects. As mentioned above, several phenotypes of MDSCs
have been identified and thoroughly characterized. The
CD33+ HLA-DR-/low MDSCs are a subtype of myeloid
cells reported by Ko et al. to have suppressive functions
in renal cell carcinoma [31]. As shown in Figure 1(a), we
identified such population with a similar gating strategy,
and differences in both diabetics and nondiabetic subjects
were also identified. For the CD15+ CD14- MDSC popula-
tion (which has been described as another important sub-
population regulating in a negative manner the immune
responses in some cancer patients) [31], samples of dia-
betics and nondiabetics show the presence of this popula-
tion in low frequency (Figure 1(b)).
3.3. Patients with DM2 Have Different Frequencies of MDSCs.
Given the suppressive role of MDSCs over other immune
cells, one of the main goals of this study was to evaluate the
frequency of MDSCs in patients with DM2 compared to
non-DM2 subjects. For this purpose, the frequency of total
cells was evaluated for both the CD33+ HLA-DR-/low and
the CD15+ CD14- phenotypes. Significant differences were
identified for the CD33+ HLA-DR-/low mononuclear




Non-DM2 (n = 21) DM2 (n = 23)
Gender (female/male) 11/10 12/11 1.000a
Age (years) 43 (q1 = 42, q3 = 50) 50 (q1 = 40, q3 = 62) 0.264b
Years with diabetes 6.0 (q1 = 2, q3 = 14)
BMI (kg/m2) 27.55 (q1 = 26:07, q3 = 30:22) 27.4 (q1 = 24:2, q3 = 28:7) 0.275b
Waist to hip ratio 0.94 (q1 = 0:91, q3 = 0:96) 0.93 (q1 = 0:89, q3 = 0:98) 0.913b
Glucose (mg/dl) 112 (q1 = 93, q3 = 117) 185.4 (q1 = 111, q3 = 233) 0.001∗b
Hb1Ac (%) 5.9 (q1 = 5:8, q3 = 6:2) 8.5 (q1 = 6:3, q3 = 10) 0.000∗b
Total cholesterol (mg/dl) 207 (q1 = 260, q3 = 231) 209.4 (q1 = 170, q3 = 230) 1.000b
cHDL (mg/dl) 48.3 (q1 = 40:9, q3 = 52:6) 49 (q1 = 38:2, q3 = 55:8) 0.869b
cLDL (mg/dl) 119.8 (q1 = 99:7, q3 = 156:3) 130.6 (q1 = 81:1, q3 = 160:9) 0.860b
aFisher’s exact test. bMann-Whitney U test. ∗P < 0:05.
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MDSCs in patients with DM2 as compared to non-DM2
(P < 0:05, Figure 1(c)). For the CD15+ CD14- MDSC cell
population, no differences between groups were found
(P > 0:05, Figure 1(d)).
3.4. CD33+ HLA-DR-/Low MDSCs Produce TGF-β and IL-
10. One of the major mechanisms by which MDSCs regulate
the T cell-mediated immune response is by the production of
























































































































Figure 1: Gating strategy and frequencies of MDSCs in DM2. (a) Dotplot APC vs. PerCP-Cy5.5 shows PBMCs and the gate mark of
the CD33+ HLA-DR-/low MDSCs. (b) Dotplot PE-Cy7 vs. PE-Cy5 shows PBMCs and PMNs and the gate mark of the CD15+ CD14-
MDSCs. (c) Frequency of CD33+ HLA-DR-/low MDSCs, comparing the group of DM2 (n = 22) with the non-DM2 group (n = 21). The
graph shows the median with interquartile ranges. (d) Frequency of CD15+ CD14- MDSCs, comparing the group of DM2 (n = 20) with the
non-DM2 group (n = 21). The graph shows the mean and standard deviation. A P value < 0.05 was considered as statistically significant which
was calculated using the statistical test of Mann-Whitney. Statistical analysis was performed with the GraphPad Prism® v5.0 software. Data
were obtained in a BD FACSCanto II® Flow Cytometer and were analyzed with the software FlowJo® v10.0.
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these cytokines in DM2 patients and controls. To demon-
strate that the CD33+ HLA-DR-/low MDSCs are an immu-
noregulatory subset of cells, we did an intracellular staining
of IL-10 and TGF-β and we found that this subpopulation
actually produces these cytokines (Figure 2), suggesting that
the immunosuppressive function of the MDSCs is also
increased in the DM2 patients.
3.5. DM2 and Non-DM2 Subjects Show a Similar Cytokine
Profile. Several reports suggest an association of increased
frequencies of MDSCs and overproduction of inflammatory
cytokines. Due to the elevation of the frequencies in the
CD33+ HLA-DR-/low MDSCs in the diabetic group, we
wondered whether this increased frequency of CD33+
HLA-DR-/low MDSCs could be related to cytokine overpro-
duction. Therefore, several proinflammatory cytokines such
as IL-1α, TNF-α, IFN-γ, IL-5, IL-12p70, and IL-17 and one
anti-inflammatory IL-10 were quantified by cytometric bead
array and analyzed through FCAP Array. The concentrations
were classified for groups and compared between groups.
Only significant differences were found in the comparison
of IL-5 (P = 0:02); the other cytokines did not show any sig-
nificant differences (Table 2). To corroborate, a correlation
analysis was made between the concentrations of the cyto-
kines and the frequencies of CD33+ HLA-DR-/low MDSCs.
No correlation between these parameters was found
(P > 0:05) (Supplementary Table 1). Finally, the same
correlation analysis was made; considering only the DM2
group, no significant correlations were identified either
(Supplementary Table 2).
3.6. CD33+ HLA-DR-/Low MDSC Increased Frequency Is
Associated with Individuals with Hypertension. It is known
that some cell subtypes in the blood are associated with an
increase in cardiovascular alterations and comorbidities,
such as the case of T helper 17 (Th17) cells that respond to
sodium increase in essential hypertension and have been
recently linked to the pathogenesis of arterial hypertension
[32, 33]. In order to identify if other variables were also asso-
ciated with the increase in MDSCs, we evaluated if hyperten-
sion had any effect on the frequency of MDSCs. For this
purpose, all subjects were polled for analysis and categorized
according to having or not hypertension (reported in their
clinical history) in two groups: hypertensive (which includes
diabetic and nondiabetic) and nonhypertensive (which
includes diabetic and nondiabetic). When the analysis was
performed on these assumptions, we found a difference in
the frequencies of CD33+ HLA-DR-/low MDSC phenotype
(P < 0:05, Figure 3(a)) between hypertensive (mean = 1:620,
SD = 0:602) and nonhypertensive (mean = 1:209, SD =
0:483) groups. These differences are not observed for the fre-
quency of CD15+ CD14- MDSCs, although a slight increase
is observed in the group that has hypertension (P > 0:05,
Figure 3(b)).
3.7. MDSC Phenotypes Correlate with Cardiovascular
Markers of Disease. Given the previously shown results,
MDSCs are elevated in the DM2 group and also in hyperten-
sive individuals. To further clarify whether differences are
associated with cardiovascular markers or diabetes markers,
a correlation analysis was carried out. It was decided to per-
form the analysis for nonparametric data; of all the variables
analyzed (age, BMI, WHR, glucose, Hb1ac%, cholesterol,
cHDL, and cLDL), only the LDL cholesterol levels have a
negatively statistically significant (P < 0:05) correlation with
the frequency of CD15+ CD14- MDSCs (Figure 4(b)). Addi-
tionally, the frequency of CD33+ HLA-DR-/low and CD15+
CD14- MDSCs has a statistically significant correlation
(P < 0:001, Figure 4(a)), and this correlation is maintained
when only the DM2 group is analyzed (P = 0:029, Supple-
mentary Table 3), so this correlation is directly associated
with DM2 condition. Data correlations with Spearman’s
rho value are summarized in Table 3.
4. Discussion
It is known that subjects with diabetes have an increased sus-
ceptibility to infectious diseases. For active tuberculosis infec-
tion, a risk of more than 5-fold has been reported in diabetics
compared to nondiabetic subjects [34, 35]. Recent reports
suggest that there are alterations in the immune cells such
as neutrophil chemotactic and phagocytic functions that
contribute to this increased susceptibility to infection in dia-
betics [36]; however, other cell populations might be associ-
ated with this phenomenon. MDSCs were linked in the last
few years with increased susceptibility to infectious diseases;
particularly, it was recently described that frequencies of
these cells are elevated in patients with tuberculosis [37].
Recently, it has been shown that low-grade inflammation
induced by obesity and infiltrating cytokine-producing adi-
pose tissue immune cells is associated with several complica-
tions of diabetics such as insulin resistance [38]. Given that
chronic inflammation is present in these individuals and
due to the previously described reports that suggest that this
might be associated with MDSC expansion, the present
report evaluated whether or not diabetes-associated low-
grade inflammatory processes might be associated with
increased frequencies of MDSCs.
It has been described that there is a basal frequency of
MDSCs in healthy individuals, although very small (around
1%) for both monocytic and polymorphonuclear MDSCs
[31]; consistent with these findings, similar frequencies in
our groups are reported. The physiological role of these cells
is thought to be associated with immune regulation by several
mechanisms, such as arginine depletion which causes a
reduced activity of T cells and a decrease in CD62L in lym-
phocytes caused by ADAM metallopeptidase domain 17
(ADAM17), and through the expansion of regulatory T
(Treg) cells by TGF-β secretion and IL-10 [20], we confirm
that our population of CD33+ HLA-DR- mononuclear
MDSCs produces IL-10 and TGF-β in both DM2 and nondi-
abetic donors.
A statistically significant rise in the frequency of CD33+
HLA-DR-/low MDSCs was found in the DM2 group; these
findings are similar to those reported by Wang et al. [39]
where they find an increased frequency of MDSC CD11b+
CD33+ and probe how these MDSCs inhibit T cell prolifera-
tion; although the phenotype is a little different (CD11b+


































































Figure 2: CD33+ HLA-DR-/low MDSCs produce IL10 and TGF-β. Representative data of the intracellular staining of IL-10 and TGF-β
on CD33+ HLA-DR-/low MDSCs. Data were obtained in a BD FACSCanto II® Flow Cytometer and were analyzed with the software
FlowJo® v10.0.
Table 2: Comparison of serum cytokine concentrations among study groups#.
Variable Non-DM2 DM2 P value
Eotaxin (x ± SD) 4475 pg/dl ± 1987 5338 pg/dl ± 2409 0.2127a
IL-1α (m ± IQR) 482.1 pg/dlq1 = 365:8, q3 = 665
415.1 pg/dl
q1 = 323:1, q3 = 487:8 0.1741
b
TNF-α (m ± IQR) 69.64 pg/dlq1 = 14:16, q3 = 149:4
42.75 pg/dl
q1 = 34:94, q3 = 133:5 0.8591
b
IFN-γ (m ± IQR) 642.8 pg/dlq1 = 397, q3 = 1534
400.1 pg/dl
q1 = 83:98, q3 = 1252 0.4202
b
IL-5 (m ± IQR) 2.850 pg/dlq1 = 0:4175, q3 = 15:89
38.4 pg/dl
q1 = 4:42, q3 = 74:72 0.0200
∗b
IL-10 (m ± IQR) 16.65 pg/dlq1 = 13:03, q3 = 32:66
26.68 pg/dl
q1 = 11:49, q3 = 46:71 0.5652
b
IL-12p70 (m ± IQR) 22.18 pg/dlq1 = 2:40, q3 = 60:23
22.65 pg/dl
q1 = 16:11, q3 = 34:25 0.9004
b
IL-17 (m ± IQR) 117.9 pg/dlq1 = 10:76, q3 = 298:4
93.97 pg/dl
q1 = 65:10, q3 = 434:9 0.9999
b
#Only the concentrations obtained above detection limits for each cytokine were considered for analysis. aStudent’s t-test. bMann-Whitney U test. ∗P < 0:05.
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CD33+ vs. CDD33+ HLA-DR-/low), both correspond to a
mononuclear immunophenotype; our findings reaffirm the
importance that MDSCs could play in the pathophysiology
of DM2 suppressing T cell response making patients suscep-
tible to some infections and also provide a link to cardiovas-
cular alterations in DM2 patients. The causes behind such
increase could be associated with the production of TGF-β
and IL-5. Several reports have described that the production
of such cytokines in diabetics and obese people is increased
and linked to insulin resistance [26]. Also, in diabetics, an
increase in signaling pathways such as JNK and IκB kinase
beta (IKKβ) has been described to be associated with insulin
resistance, and these same signaling pathways are responsible
of MDSC expansion in bone marrow [40–43]. Therefore, the
low-grade inflammation process characteristic of diabetics
could be associated with such observed expansion. Surpris-
ingly, our results did not show differences in the cytokine
profile, perhaps because all the patients were already under
medical oversight and treatment. In our sample, there were
no differences in the BMI (which is one of the variables asso-
ciated with low-grade inflammation). Interestingly, the only
cytokine that is elevated in our sample of DM2 was IL-5. This
cytokine that has been reported to be increased in those
patients with DM2 and tuberculosis [44], common comor-
bidity associated with immunodeficiency in DM2 patients;
nevertheless, further investigation is needed to confirm the
role of IL-5 in susceptibility to infections in DM2.
Systemic arterial hypertension (SAH) is a common
comorbidity of DM2 patients, according to the National
Health and Nutrition Survey (ENSANUT, acronym in Span-
ish) in 2016; in Mexico, patients with a previous diagnosis of
diabetes have a prevalence of 57.6% with hypertension [45].
Therefore, when we analyzed according to SAH, a significant


































Figure 3: Frequency of CD33+ HLA-DR-/low and CD15+ CD14- MDSCs comparing if the subjects have hypertension in both groups (DM2
and non-DM2). (a) Frequency of CD33+ HLA-DR-/low MDSCs (hypertensive n = 16, nonhypertensive n = 27). (b) Frequency of CD15+
CD14- MDSCs (hypertensive n = 15, nonhypertensive n = 26). The graphs show the median and interquartile ranges. It was considered as
statistically significant if P value < 0.05∗ which was calculated using the statistical t-test for unpaired samples. Statistical analysis was
performed with the GraphPad Prism® v5.0 software.
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Figure 4: Correlation of MDSC frequency with cardiovascular markers. (a) Correlation between Freq. CD15+ CD14- and CD33+ HLA-
DR-/low MDSCs. Data from 44 subjects, including groups in DM2 and nondiabetic controls. (b) Correlation between the concentration
of LDL cholesterol and Freq. CD15+ CD14- MDSCs. Shown data are from 44 subjects (DM2 and nondiabetic controls). It was
considered as statistically significant if value of P < 0:05. Statistical analysis was performed with the GraphPad Prism ® v5.0 software.
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documented that hypertension has an important inflamma-
tory component particularly associated with Th17 cells that
have a high response to salt concentrations [46]. Given that
these cells are able to produce IL-6 and other cytokines [47]
that are able to induce proliferation of MDSCs, our hypothe-
sis is that such phenomena are intertwined, meaning that
MDSC increased frequencies are probably a consequence of
inflammatory processes from diabetes, obesity, and hyper-
tension. This is further supported by our own results given
that increased frequency of MDSC cells correlates between
the two phenotypes; high levels of LDL cholesterol correlated
negatively with CD15+ CD14- MDSCs, and this could be
related to the generation of atheromatous plaques in blood
vessels given that an increase of such inflammatory cells with
Table 3: Correlation analysis of variables with the frequency of MDSCs#.
Freq. MDSCs CD15+ CD14- Freq. MDSCs CD33+ HLA-DR-
Age
Correlation coefficient -0.083 -0.117
Significance (two-tailed) 0.607 0.456
N 41 43
Time of diagnosis (years)
Correlation coefficient -0.080 0.039
Significance (two-tailed) 0.744 0.869
N 19 20
BMI (kg/m2)
Correlation coefficient 0.180 0.054
Significance (two-tailed) 0.259 0.731
N 41 43
Waist-hip ratio
Correlation coefficient -0.259 -0.139
Significance (two-tailed) 0.107 0.378
N 40 42
Fasting glucose
Correlation coefficient -0.097 0.252
Significance (two-tailed) 0.547 0.103
N 41 43
HbA1c (%)
Correlation coefficient -0.040 0.255
Significance (two-tailed) 0.802 0.100
N 41 43
Total cholesterol (mg/dl)
Correlation coefficient -0.284 -0.083
Significance (two-tailed) 0.071 0.597
N 41 43
cHDL (mg/dl)
Correlation coefficient 0.104 -0.044
Significance (two-tailed) 0.518 0.779
N 41 43
cLDL (mg/dl)
Correlation coefficient -0.364∗ -0.110
Significance (two-tailed) 0.019 0.482
N 41 43
Triglycerides (mg/dl)
Correlation coefficient -0.068 -0.068
Significance (two-tailed) 0.675 0.665
N 41 43
Freq. MDSCs CD15+ CD14-
Correlation coefficient 1.000 0.511∗∗
Significance (two-tailed) 0.001
N 41 40
Freq. MDSCs CD33+ HLA-DR-
Correlation coefficient 0.511∗∗ 1.000
Significance (two-tailed) 0.001
N 40 43
#Correlations were calculated with Spearman’s rho. Differences in the sample size for each correlation may differ depending on the availability of the data for
such patients or controls. ∗P < 0:05; ∗∗P < 0:01.
8 Journal of Diabetes Research
phagocytic functions such as these is able to adhere to such
plaques. These hypotheses need to be confirmed by experi-
mental observations.
5. Conclusion
Our group of DM2 patients have an increased frequency of
mononuclear MDSCs CD33+ HLA-DR-/low that produce
TGF-β and IL-10. DM2 and non-DM2 subjects show a sim-
ilar cytokine profile, but the DM2 patients have an increased
concentration of IL-5. CD33+HLA-DR-/low MDSCs are
associated with other complications of diabetics such as
hypertension and cardiovascular markers of the disease
(cLDL).
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